Rhythm Pharmaceuticals
RYTMBiotechUnited States
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
10
Indications↗
Distinct diseases across all programs
27
Clinical Trials↗
All sponsored trials (all statuses)
3
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Approved1
Phase 31
Phase 22
By Therapeutic Area
top 3
Rare Disease
240%
Metabolic & Endocrine
120%
Nephrology
120%
R&D Momentum
37/100
Pipeline Velocity
11/100
Trial Completion Rate
100/100
Pipeline Concentration
28/100
Pipeline Freshness
77/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Key Events
Mar 5, 2026TrialSETMELANOTIDE-RM: Setmelanotide in Rare Obesity
Nov 10, 2025TrialA Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Sep 23, 2025TrialA Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Mar 4, 2025TrialA Study of Setmelanotide in Patients With Prader-Willi Syndrome
Oct 21, 2024TrialOpen-Label Extension Study of Setmelanotide
Jul 11, 2024TrialA Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Mar 5, 2024TrialA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Apr 26, 2023TrialA Trial of Setmelanotide in Acquired Hypothalamic Obesity
4 more events
Mar 8, 2022TrialSetmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Dec 21, 2021TrialPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Dec 10, 2021TrialEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Nov 30, 2021TrialDAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Details
Company Info
Therapeutic Focus
Metabolic & EndocrineOtherRare DiseaseNephrology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Nephrology
Rare Disease
Metabolic & Endocrine
Genetic Obesity
ImcivreeApproved
Morbid Obesity
ImcivreeApproved
Nephrology
Renal Insufficiency
ImcivreeApproved
Rare Disease
Hypothalamic Obesity
ImcivreePhase 3
BivamelagonPhase 2
Unknown / Other
Genetic Disorder
ImcivreePhase 2
Regulatory
Regulatory Timeline
20201 event
FDANov 25
Imcivree — IMCIVREE
Application NDA213793 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)